Loading...
Loading...
BXRX| Name | Value |
|---|---|
| Revenues | 30.0K |
| Cost of Revenue | 104.0K |
| Gross Profit | -74.0K |
| Operating Expense | 4,033.0K |
| Operating I/L | -7,045.0K |
| Other Income/Expense | -3,268.0K |
| Interest Income | 0.0K |
| Pretax | -7,301.0K |
| Income Tax Expense | 3,086.0K |
| Net Income/Loss | -7,375.0K |
Baudax Bio, Inc. is a pharmaceutical company specializing in developing and commercializing products for hospital and acute care settings. Their flagship product, ANJESO (meloxicam) injection, is used for managing moderate to severe pain, either alone or in combination with non-NSAID analgesics. The company's product pipeline includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) in phase II clinical trial; BX2000, an ultra-short acting NMBA in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine.
